1
|
Ghareh H, Alonso-Lozares I, Schetters D, Herman RJ, Heistek TS, Van Mourik Y, Jean-Richard-Dit-Bressel P, Zernig G, Mansvelder HD, De Vries TJ, Marchant NJ. Role of anterior insula cortex in context-induced relapse of nicotine-seeking. eLife 2022; 11:75609. [PMID: 35536612 PMCID: PMC9119676 DOI: 10.7554/elife.75609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2021] [Accepted: 05/09/2022] [Indexed: 11/15/2022] Open
Abstract
Tobacco use is the leading cause of preventable death worldwide, and relapse during abstinence remains the critical barrier to successful treatment of tobacco addiction. During abstinence, environmental contexts associated with nicotine use can induce craving and contribute to relapse. The insular cortex (IC) is thought to be a critical substrate of nicotine addiction and relapse. However, its specific role in context-induced relapse of nicotine-seeking is not fully known. In this study, we report a novel rodent model of context-induced relapse to nicotine-seeking after punishment-imposed abstinence, which models self-imposed abstinence through increasing negative consequences of excessive drug use. Using the neuronal activity marker Fos we find that the anterior (aIC), but not the middle or posterior IC, shows increased activity during context-induced relapse. Combining Fos with retrograde labeling of aIC inputs, we show projections to aIC from contralateral aIC and basolateral amygdala exhibit increased activity during context-induced relapse. Next, we used fiber photometry in aIC and observed phasic increases in aIC activity around nicotine-seeking responses during self-administration, punishment, and the context-induced relapse tests. Next, we used chemogenetic inhibition in both male and female rats to determine whether activity in aIC is necessary for context-induced relapse. We found that chemogenetic inhibition of aIC decreased context-induced nicotine-seeking after either punishment- or extinction-imposed abstinence. These findings highlight the critical role nicotine-associated contexts play in promoting relapse, and they show that aIC activity is critical for this context-induced relapse following both punishment and extinction-imposed abstinence.
Collapse
Affiliation(s)
- Hussein Ghareh
- Department of Psychiatry, Medical University of Innsbruck, Innsbruck, Austria
| | - Isis Alonso-Lozares
- Department of Anatomy and Neurosciences, Amsterdam University Medical Centers, Amsterdam, Netherlands
| | - Dustin Schetters
- Department of Anatomy and Neurosciences, Amsterdam University Medical Centers, Amsterdam, Netherlands
| | - Rae J Herman
- Department of Anatomy and Neurosciences, Amsterdam University Medical Centers, Amsterdam, Netherlands
| | - Tim S Heistek
- Department of Integrative Neurophysiology, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - Yvar Van Mourik
- Department of Anatomy and Neurosciences, Amsterdam University Medical Centers, Amsterdam, Netherlands
| | | | - Gerald Zernig
- Department of Psychiatry, Medical University of Innsbruck, Innsbruck, Austria
| | - Huibert D Mansvelder
- Department of Integrative Neurophysiology, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - Taco J De Vries
- Department of Anatomy and Neurosciences, Amsterdam University Medical Centers, Amsterdam, Netherlands
| | - Nathan J Marchant
- Department of Anatomy and Neurosciences, Amsterdam University Medical Centers, Amsterdam, Netherlands
| |
Collapse
|
2
|
Moro F, Giannotti G, Caffino L, Marzo CM, Di Clemente A, Fumagalli F, Cervo L. Lasting reduction of nicotine-seeking behavior by chronic N-acetylcysteine during experimental cue-exposure therapy. Addict Biol 2020; 25:e12771. [PMID: 31132808 DOI: 10.1111/adb.12771] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2018] [Revised: 02/10/2019] [Accepted: 04/09/2019] [Indexed: 10/26/2022]
Abstract
Nicotine-associated cues can trigger reinstatement in humans as well as in animal models of drug addiction. To date, no behavioral intervention or pharmacological treatment has been effective in preventing relapse in the long term. A large body of evidence indicates that N-acetylcysteine (N-AC) blunts the activation of glutamatergic (GLUergic) neurons in the nucleus accumbens (Nacc) associated with reinstatement. We evaluated the effect of an experimental cue exposure therapy (eCET) alone or in combination with N-AC to verify whether restoring GLU homeostasis enhances extinction of nicotine-associated cues. Rats were trained to associate discriminative stimuli with intravenous nicotine or saline self-administration. Reinforced response was followed by cue signals. After rats met the self-administration criteria, the lasting anti-relapse activity of i.p. N-AC or vehicle was assessed in three different experimental conditions after 14 days of treatment: treatment + eCET; treatment + lever-presses extinction (LP-EXT); and treatment + abstinence. N-AC 100 mg/kg, but not 60 mg/kg, induced anti-relapse activity that persisted 50 days after treatment only when paired with either LP-EXT or eCET with the greater activity found in the latter condition. To identify potential mechanisms for behavioral results, separate groups of rats that received either N-AC or vehicle + eCET were killed at different time points for Nacc Western-blot analysis. Seven days after treatment, chronic N-AC restored the expression of proteins crucial for GLU homeostasis, while at 50 days, it increased the expression of type II metabotropic GLU receptors. These results suggest that N-AC treatment in combination with eCET may offer a novel strategy to prevent relapse in nicotine addiction.
Collapse
Affiliation(s)
- Federico Moro
- Experimental Psychopharmacology, Department of Neuroscience Mario Negri Institute for Pharmacological Research—IRCCS Milan Italy
| | | | - Lucia Caffino
- Department of Pharmacological and Biomolecular Sciences Università degli Studi di Milano Milan Italy
| | | | - Angelo Di Clemente
- Experimental Psychopharmacology, Department of Neuroscience Mario Negri Institute for Pharmacological Research—IRCCS Milan Italy
| | - Fabio Fumagalli
- Department of Pharmacological and Biomolecular Sciences Università degli Studi di Milano Milan Italy
| | - Luigi Cervo
- Experimental Psychopharmacology, Department of Neuroscience Mario Negri Institute for Pharmacological Research—IRCCS Milan Italy
| |
Collapse
|
3
|
Vengeliene V, Roßmanith M, Takahashi TT, Alberati D, Behl B, Bespalov A, Spanagel R. Targeting Glycine Reuptake in Alcohol Seeking and Relapse. J Pharmacol Exp Ther 2018; 365:202-211. [DOI: 10.1124/jpet.117.244822] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2017] [Accepted: 01/02/2018] [Indexed: 11/22/2022] Open
|
4
|
Moro F, Orrù A, Marzo CM, Di Clemente A, Cervo L. mGluR2/3 mediates short-term control of nicotine-seeking by acute systemic N-acetylcysteine. Addict Biol 2018; 23:28-40. [PMID: 27558879 DOI: 10.1111/adb.12443] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2016] [Revised: 06/24/2016] [Accepted: 08/01/2016] [Indexed: 12/26/2022]
Abstract
Chronic self-administration of nicotine induces maladaptive changes in the cortico-accumbal glutamate (Glu) network. Consequently, re-exposure to nicotine-associated cues raises extracellular Glu in the nucleus accumbens reinstating drug-seeking. Restoring basal concentrations of extracellular Glu, thereby increasing tonic activation of the presynaptic group II metabotropic Glu receptors (mGluR2/3) with N-acetylcysteine (N-AC), might offer a valid therapeutic approach for maintaining smoking abstinence. Although N-AC modulates nicotine-seeking behavior by drug-associated stimuli in abstinent rats, it is still unclear whether it occurs through activation of mGluR2/3. Male Wistar rats were trained to associate discriminative stimuli (SD s) with the availability of intravenous nicotine (0.03 mg/kg/65 µl/2-second/infusion) or oral saccharin (100 µl of 50 mg/l) self-administration versus non-reward. Reinforced response was followed by a cue signaling 20-second time-out (CSs). Once the training criterion was met, rats underwent lever press extinction, without reinforcers, SD s and CSs. Re-exposure to nicotine or saccharin SD+ /CS+ , but not non-reward SD- /CS- , revived responding on the previously reinforced lever. Acute N-AC, 100 but not 60 or 30 mg/kg i.p., reduced cue-induced nicotine-seeking. N-AC 100 mg/kg did not modify cue-induced saccharin-seeking behavior or influenced locomotor activity. Blocking mGluR2/3 with the selective antagonist LY341495, 1 mg/kg i.p., completely prevented the antirelapse activity of N-AC. The finding that N-AC prevents cue-induced nicotine-seeking by stimulating mGluR2/3 might indicate a therapeutic opportunity for acute cue-controlled nicotine-seeking. Future studies could evaluate the persistent effects of chronic N-AC in promoting enduring suppression of nicotine-cue conditioned responding.
Collapse
Affiliation(s)
- Federico Moro
- Experimental Psychopharmacology, Department of Neuroscience; IRCCS-Mario Negri Institute for Pharmacological Research; Italy
| | - Alessandro Orrù
- Experimental Psychopharmacology, Department of Neuroscience; IRCCS-Mario Negri Institute for Pharmacological Research; Italy
| | - Claudio Marcello Marzo
- Experimental Psychopharmacology, Department of Neuroscience; IRCCS-Mario Negri Institute for Pharmacological Research; Italy
| | - Angelo Di Clemente
- Experimental Psychopharmacology, Department of Neuroscience; IRCCS-Mario Negri Institute for Pharmacological Research; Italy
| | - Luigi Cervo
- Experimental Psychopharmacology, Department of Neuroscience; IRCCS-Mario Negri Institute for Pharmacological Research; Italy
| |
Collapse
|
5
|
Effects of menthol and its interaction with nicotine-conditioned cue on nicotine-seeking behavior in rats. Psychopharmacology (Berl) 2017; 234:3443-3453. [PMID: 28918457 PMCID: PMC5693741 DOI: 10.1007/s00213-017-4736-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Accepted: 08/24/2017] [Indexed: 10/18/2022]
Abstract
RATIONALE Increasing clinical evidence suggests that menthol, a significant flavoring additive in tobacco products, may contribute to smoking and nicotine dependence. Relapse to smoking behavior presents a formidable challenge for the treatment of tobacco addiction. An unresolved issue is whether the mentholation of tobacco products precipitates relapse to tobacco use in abstinent smokers. OBJECTIVES The present study examined the effects of menthol on the perseverance and relapse of nicotine-seeking behavior in rats. METHODS Male Sprague-Dawley rats were trained to press a lever for intravenous nicotine self-administration (0.03 mg/kg/infusion) under a fixed-ratio five schedule of reinforcement. Each nicotine infusion was signaled by the presentation of a sensory stimulus that was established as a discrete nicotine-conditioned cue. Five minutes prior to the sessions, the rats received an intraperitoneal injection of menthol (0.1 mg/kg) or vehicle. In the subsequent extinction test sessions, nicotine was unavailable with or without menthol and/or the nicotine-conditioned cue. The reinstatement tests were performed the following day after the extinction criterion was met. Menthol was also tested on food-seeking responses. In a subset of nicotine-trained rats, a transient receptor potential melastatin 8 (TRPM8) antagonist RQ-00203078 was given prior to menthol administration. RESULTS Continued administration of menthol sustained responses on the previously active and nicotine-reinforced lever in the extinction tests. The readministration of menthol after extinction reinstated active lever responses. In both the extinction and the reinstatement tests, a combination of pre-session menthol administration and cue representation during the session produced a more robust behavioral effect than either menthol or the cue alone. No such effects of menthol was observed in food trained rats. RQ-00203078 did not change menthol effect on nicotine seeking. CONCLUSION These data demonstrated that menthol specifically sustained and reinstated nicotine-seeking behavior, and this effect was independent of TRPM8 activity. These findings suggest that menthol in most tobacco products, even not menthol labeled, may contribute to the perseverance of and relapse to tobacco-seeking behavior.
Collapse
|
6
|
Walker LE, Frigerio F, Ravizza T, Ricci E, Tse K, Jenkins RE, Sills GJ, Jorgensen A, Porcu L, Thippeswamy T, Alapirtti T, Peltola J, Brodie MJ, Park BK, Marson AG, Antoine DJ, Vezzani A, Pirmohamed M. Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. J Clin Invest 2017; 127:2118-2132. [PMID: 28504645 PMCID: PMC5451237 DOI: 10.1172/jci92001] [Citation(s) in RCA: 70] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Accepted: 03/16/2017] [Indexed: 01/09/2023] Open
Abstract
Approximately 30% of epilepsy patients do not respond to antiepileptic drugs, representing an unmet medical need. There is evidence that neuroinflammation plays a pathogenic role in drug-resistant epilepsy. The high-mobility group box 1 (HMGB1)/TLR4 axis is a key initiator of neuroinflammation following epileptogenic injuries, and its activation contributes to seizure generation in animal models. However, further work is required to understand the role of HMGB1 and its isoforms in epileptogenesis and drug resistance. Using a combination of animal models and sera from clinically well-characterized patients, we have demonstrated that there are dynamic changes in HMGB1 isoforms in the brain and blood of animals undergoing epileptogenesis. The pathologic disulfide HMGB1 isoform progressively increased in blood before epilepsy onset and prospectively identified animals that developed the disease. Consistent with animal data, we observed early expression of disulfide HMGB1 in patients with newly diagnosed epilepsy, and its persistence was associated with subsequent seizures. In contrast with patients with well-controlled epilepsy, patients with chronic, drug-refractory epilepsy persistently expressed the acetylated, disulfide HMGB1 isoforms. Moreover, treatment of animals with antiinflammatory drugs during epileptogenesis prevented both disease progression and blood increase in HMGB1 isoforms. Our data suggest that HMGB1 isoforms are mechanistic biomarkers for epileptogenesis and drug-resistant epilepsy in humans, necessitating evaluation in larger-scale prospective studies.
Collapse
Affiliation(s)
- Lauren Elizabeth Walker
- Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | | | | | - Emanuele Ricci
- Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Karen Tse
- Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Rosalind E Jenkins
- Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Graeme John Sills
- Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Andrea Jorgensen
- Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Luca Porcu
- Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | - Thimmasettappa Thippeswamy
- Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, Iowa, USA
| | - Tiina Alapirtti
- Department of Neurology and Rehabilitation, Tampere University Hospital, Tampere, Finland
| | - Jukka Peltola
- Department of Neurology and Rehabilitation, Tampere University Hospital, Tampere, Finland
| | | | - Brian Kevin Park
- Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Anthony Guy Marson
- Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Daniel James Antoine
- Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | | | - Munir Pirmohamed
- Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| |
Collapse
|
7
|
Cioffi CL, Liu S, Wolf MA, Guzzo PR, Sadalapure K, Parthasarathy V, Loong DTJ, Maeng JH, Carulli E, Fang X, Karunakaran K, Matta L, Choo SH, Panduga S, Buckle RN, Davis RN, Sakwa SA, Gupta P, Sargent BJ, Moore NA, Luche MM, Carr GJ, Khmelnitsky YL, Ismail J, Chung M, Bai M, Leong WY, Sachdev N, Swaminathan S, Mhyre AJ. Synthesis and Biological Evaluation of N-((1-(4-(Sulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide Inhibitors of Glycine Transporter-1. J Med Chem 2016; 59:8473-94. [PMID: 27559615 DOI: 10.1021/acs.jmedchem.6b00914] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
We previously disclosed the discovery of rationally designed N-((1-(4-(propylsulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1 (GlyT-1), represented by analogues 10 and 11. We describe herein further structure-activity relationship exploration of this series via an optimization strategy that primarily focused on the sulfonamide and benzamide appendages of the scaffold. These efforts led to the identification of advanced leads possessing a desirable balance of excellent in vitro GlyT-1 potency and selectivity, favorable ADME and in vitro pharmacological profiles, and suitable pharmacokinetic and safety characteristics. Representative analogue (+)-67 exhibited robust in vivo activity in the cerebral spinal fluid glycine biomarker model in both rodents and nonhuman primates. Furthermore, rodent microdialysis experiments also demonstrated that oral administration of (+)-67 significantly elevated extracellular glycine levels within the medial prefrontal cortex (mPFC).
Collapse
Affiliation(s)
- Christopher L Cioffi
- Department of Medicinal Chemistry, AMRI , East Campus, 3 University Place, Rensselaer, New York 12144, United States
| | - Shuang Liu
- Department of Medicinal Chemistry, AMRI , East Campus, 3 University Place, Rensselaer, New York 12144, United States
| | - Mark A Wolf
- Department of Medicinal Chemistry, AMRI , East Campus, 3 University Place, Rensselaer, New York 12144, United States
| | - Peter R Guzzo
- Department of Medicinal Chemistry, AMRI , East Campus, 3 University Place, Rensselaer, New York 12144, United States
| | - Kashinath Sadalapure
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Visweswaran Parthasarathy
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - David T J Loong
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Jun-Ho Maeng
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Edmund Carulli
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Xiao Fang
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Kalesh Karunakaran
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Lakshman Matta
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Sok Hui Choo
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Shailijia Panduga
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Ronald N Buckle
- Department of Medicinal Chemistry, AMRI , East Campus, 3 University Place, Rensselaer, New York 12144, United States
| | - Randall N Davis
- Department of Medicinal Chemistry, AMRI , East Campus, 3 University Place, Rensselaer, New York 12144, United States
| | - Samuel A Sakwa
- Department of Medicinal Chemistry, AMRI , East Campus, 3 University Place, Rensselaer, New York 12144, United States
| | - Priya Gupta
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Bruce J Sargent
- Department of Medicinal Chemistry, AMRI , East Campus, 3 University Place, Rensselaer, New York 12144, United States
| | - Nicholas A Moore
- Department of Medicinal Chemistry, AMRI , East Campus, 3 University Place, Rensselaer, New York 12144, United States
| | - Michele M Luche
- Bothell Research Center, AMRI , 22215 26th Ave SE, Bothell, Washington 98021-4425, United States
| | - Grant J Carr
- Bothell Research Center, AMRI , 22215 26th Ave SE, Bothell, Washington 98021-4425, United States
| | - Yuri L Khmelnitsky
- Drug Metabolism and Pharmacokinetics, AMRI , East Campus, 17 University Place, Rensselaer, New York 12144, United States
| | - Jiffry Ismail
- Drug Metabolism and Pharmacokinetics, AMRI , East Campus, 17 University Place, Rensselaer, New York 12144, United States
| | - Mark Chung
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Mei Bai
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Wei Yee Leong
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Nidhi Sachdev
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Srividya Swaminathan
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Andrew J Mhyre
- Bothell Research Center, AMRI , 22215 26th Ave SE, Bothell, Washington 98021-4425, United States
| |
Collapse
|
8
|
Venniro M, Caprioli D, Shaham Y. Animal models of drug relapse and craving: From drug priming-induced reinstatement to incubation of craving after voluntary abstinence. PROGRESS IN BRAIN RESEARCH 2015; 224:25-52. [PMID: 26822352 DOI: 10.1016/bs.pbr.2015.08.004] [Citation(s) in RCA: 207] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
High rates of relapse to drug use during abstinence is a defining feature of drug addiction. In abstinent drug users, drug relapse is often precipitated by acute exposure to the self-administered drug, drug-associated cues, stress, as well as by short-term and protracted withdrawal symptoms. In this review, we discuss different animal models that have been used to study behavioral and neuropharmacological mechanisms of these relapse-related phenomena. In the first part, we discuss relapse models in which abstinence is achieved through extinction training, including the established reinstatement model, as well as the reacquisition and resurgence models. In the second part, we discuss recent animal models in which drug relapse is assessed after either forced abstinence (e.g., the incubation of drug craving model) or voluntary (self-imposed) abstinence achieved either by introducing adverse consequences to ongoing drug self-administration (e.g., punishment) or by an alternative nondrug reward using a discrete choice (drug vs. palatable food) procedure. We conclude by briefly discussing the potential implications of the recent developments of animal models of drug relapse after voluntary abstinence to the development of medications for relapse prevention.
Collapse
Affiliation(s)
- Marco Venniro
- Behavioral Neuroscience Research Branch, Intramural Research Program, NIDA, NIH, Baltimore, MD, USA; Department of Public Health and Community Medicine, Neuropsychopharmacology Laboratory, Section of Pharmacology, University of Verona, Verona, Italy.
| | - Daniele Caprioli
- Behavioral Neuroscience Research Branch, Intramural Research Program, NIDA, NIH, Baltimore, MD, USA
| | - Yavin Shaham
- Behavioral Neuroscience Research Branch, Intramural Research Program, NIDA, NIH, Baltimore, MD, USA.
| |
Collapse
|
9
|
Abstract
The aim of Addiction Biology is to advance our understanding of the action of drugs of abuse and addictive processes via the publication of high-impact clinical and pre-clinical findings resulting from behavioral, molecular, genetic, biochemical, neurobiological and pharmacological research. As of 2013, Addiction Biology is ranked number 1 in the category of Substance Abuse journals (SCI). Occasionally, Addiction Biology likes to highlight via review important findings focused on a particular topic and recently published in the journal. The current review summarizes a number of key publications from Addiction Biology that have contributed to the current knowledge of nicotine research, comprising a wide spectrum of approaches, both clinical and pre-clinical, at the cellular, molecular, systems and behavioral levels. A number of findings from human studies have identified, using imaging techniques, alterations in common brain circuits, as well as morphological and network activity changes, associated with tobacco use. Furthermore, both clinical and pre-clinical studies have characterized a number of mechanistic targets critical to understanding the effects of nicotine and tobacco addiction. Together, these findings will undoubtedly drive future studies examining the dramatic impact of tobacco use and the development of treatments to counter nicotine dependence.
Collapse
Affiliation(s)
- Rick E. Bernardi
- Institute of Psychopharmacology; Central Institute of Mental Health; Medical Faculty Mannheim/Heidelberg University; Germany
| |
Collapse
|
10
|
Perry CJ, Zbukvic I, Kim JH, Lawrence AJ. Role of cues and contexts on drug-seeking behaviour. Br J Pharmacol 2014; 171:4636-72. [PMID: 24749941 PMCID: PMC4209936 DOI: 10.1111/bph.12735] [Citation(s) in RCA: 89] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2013] [Revised: 04/04/2014] [Accepted: 04/10/2014] [Indexed: 01/15/2023] Open
Abstract
Environmental stimuli are powerful mediators of craving and relapse in substance-abuse disorders. This review examined how animal models have been used to investigate the cognitive mechanisms through which cues are able to affect drug-seeking behaviour. We address how animal models can describe the way drug-associated cues come to facilitate the development and persistence of drug taking, as well as how these cues are critical to the tendency to relapse that characterizes substance-abuse disorders. Drug-associated cues acquire properties of conditioned reinforcement, incentive motivation and discriminative control, which allow them to influence drug-seeking behaviour. Using these models, researchers have been able to investigate the pharmacology subserving the behavioural impact of environmental stimuli, some of which we highlight. Subsequently, we examine whether the impact of drug-associated stimuli can be attenuated via a process of extinction, and how this question is addressed in the laboratory. We discuss how preclinical research has been translated into behavioural therapies targeting substance abuse, as well as highlight potential developments to therapies that might produce more enduring changes in behaviour.
Collapse
Affiliation(s)
- Christina J Perry
- Behavioural Neuroscience Division, The Florey Institute of Neuroscience and Mental HealthParkville, Vic., Australia
- Florey Department of Neuroscience and Mental Health, University of MelbourneParkville, Vic., Australia
| | - Isabel Zbukvic
- Behavioural Neuroscience Division, The Florey Institute of Neuroscience and Mental HealthParkville, Vic., Australia
- Florey Department of Neuroscience and Mental Health, University of MelbourneParkville, Vic., Australia
| | - Jee Hyun Kim
- Behavioural Neuroscience Division, The Florey Institute of Neuroscience and Mental HealthParkville, Vic., Australia
- Florey Department of Neuroscience and Mental Health, University of MelbourneParkville, Vic., Australia
| | - Andrew J Lawrence
- Behavioural Neuroscience Division, The Florey Institute of Neuroscience and Mental HealthParkville, Vic., Australia
- Florey Department of Neuroscience and Mental Health, University of MelbourneParkville, Vic., Australia
| |
Collapse
|